MAPKAP1 and neoplasm: Liu et al. found that mutations of key Sin1 residues mediating phosphatidylinositol (3,4,5)-triphosphate (PIP3) interactions inactivate mTORC2, whereas patient-derived mutations in the Sin1-PH domain pathologically increased mTORC2 activity, promoting cell growth and tumor formation [82].